奥比努祖马布诱导的炎症性肠病-如胰炎:第一个病例报告
Raquel R Mendes1, Pedro C Figueiredo1, Isabel Andrade2
1Gastroenterology Department, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.
GE Portuguese journal of gastroenterology
|August 8, 2024
概括
反CD20抗体Obinutuzumab可以引起胰腺炎,模仿炎症性肠病 (IBD). 这一案例凸显了在淋巴瘤患者出现胃肠道症状时考虑药物毒性的重要性.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 奥本图祖马布是一种II型抗CD20单克隆抗体,用于癌症治疗.
- 与rituximab相比,它与更高的毒性有关,对胃肠道副作用的数据有限.
- 接受化疗的毛囊性非霍奇金淋巴瘤患者有风险.
研究的目的:
- 报告第一个由obinutuzumab引起的胰腺炎病例.
- 讨论区分药物诱导性结肠炎与炎症性肠病 (IBD) 的诊断挑战.
- 突出管理和结果的影响.
主要方法:
- 一个47岁的女性患有第四期卵泡非霍奇金淋巴瘤的病例介绍.
- 慢性血性腹和缺铁性贫血的临床表现.
- 内镜和组织学评估以区分IBD.
主要成果:
- 患者出现了模仿IBD的症状.
- 确立了由奥比努祖马布诱导的胰腺炎的诊断.
- 停止使用奥比努祖马布导致临床改善.
结论:
- 奥比努祖马布可以诱导胰腺炎,这是一个罕见但显著的胃肠道副作用.
- 多学科的方法对于IBD的差异诊断至关重要,在患者治疗obinutuzumab.
- 早期识别和戒毒是成功管理的关键.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
Inflammatory Bowel Disease II: Crohn's Disease
206
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
206
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Chronic Bowel Disorders: Introduction
436
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
436


